Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
S651962-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $90.90 | |
S651962-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $150.90 | |
S651962-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $300.90 | |
S651962-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $450.90 | |
S651962-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $750.90 |
Specifications & Purity | ≥98% |
---|---|
Biochemical and Physiological Mechanisms | (Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | (Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid. In Vitro (Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion of gastric acid. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:CCK-B receptor |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 1-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3H-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea |
---|---|
INCHI | InChI=1S/C28H30N6O3/c1-28(2,3)23(35)17-34-22-14-6-5-12-20(22)24(21-13-7-8-15-30-21)32-25(26(34)36)33-27(37)31-19-11-9-10-18(16-19)29-4/h5-16,25,29H,17H2,1-4H3,(H2,31,33,37) |
InChi Key | YDZYKNJZCVIKPP-UHFFFAOYSA-N |
Canonical SMILES | CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)NC3=CC=CC(=C3)NC)C4=CC=CC=N4 |
Isomeric SMILES | CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)NC3=CC=CC(=C3)NC)C4=CC=CC=N4 |
PubChem CID | 21842392 |
Molecular Weight | 498.58 |
Enter Lot Number to search for COA:
Solubility | DMSO : 125 mg/mL (250.71 mM; Need ultrasonic) |
---|